drugset
drugset / Trial / NCT06822868

A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

NCT06822868 ↗

Phase 1 Recruiting 24 enrolled Kai Hu
NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study to Investigate the Safety, Efficacy, and Cellular Metabolism of CT1190B CAR-T Cell therapy, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.

Timeline

Start
2025-02-10
Primary completion
2025-09-30
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CT1190B Cell therapy — —

Indications

B-cell non-Hodgkin lymphoma